(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 48.39% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.58%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.43%.
Liquidia's revenue in 2026 is $450,907,000.On average, 10 Wall Street analysts forecast LQDA's revenue for 2026 to be $66,747,675,108, with the lowest LQDA revenue forecast at $51,449,710,547, and the highest LQDA revenue forecast at $72,371,518,729. On average, 10 Wall Street analysts forecast LQDA's revenue for 2027 to be $112,065,131,532, with the lowest LQDA revenue forecast at $77,093,112,729, and the highest LQDA revenue forecast at $136,232,532,102.
In 2028, LQDA is forecast to generate $125,491,465,182 in revenue, with the lowest revenue forecast at $99,533,886,792 and the highest revenue forecast at $146,168,019,003.